hiPSC-derived cardiomyocyte engraftment in a nonhuman primate model of right ventricular pressure overload – definitive study

The PI of this project was:

This project was funded by: RSP grant, Mayo Clinic sponsor

The term of this project was: October 2020 to June 2021

The number of subjects scanned during this project was: 28

The specific objective of this proposed work is to evaluate safety of the engraftment of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) after injection into an immunosuppressed primate diseased right ventricle (banded pulmonary artery).

The goals of the study are to determine whether human stem cells will successfully integrate into the cardiac tissue and whether cardiac function after pulmonary artery banding improves with the stem cell treatment.

Cardiac status will be evaluated using echocardiography, loop recorder analysis, and bloodwork according to the attached timeline/figure.